Skip to main content

IDEXX Laboratories Inc. (IDXX) Stock

IDEXX Laboratories Inc. Stock Details, Movements and Public Alerts

Stock Details

IDEXX Laboratories Inc. (IDXX), a prominent company in the life sciences sector within the in vitro & in vivo diagnostic substances industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $565.19. Over the past 52 weeks, it has ranged between $356.14 and $568.47. This places the current price at 99.4% of its 52-week high and 58.7% above its 52-week low. Recent trading volume was recorded at 1,071,471. The International Securities Identification Number (ISIN) for this stock is US45168D1046.

Market Cap

$42.73B

52-Week High

$568.47

-0.58% from high

52-Week Low

$356.14

+58.70% from low

Avg Daily Volume

1,071,471

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

49.01

Above market average

Forward P/E

44.05

Earnings expected to grow

PEG Ratio

4.39

Potentially overvalued

Price to Book

29.50

EV/EBITDA

33.82

EPS (TTM)

$10.84

Price to Sales

10.87

Beta

1.55

More volatile than market

How is IDXX valued relative to its earnings and growth?
IDEXX Laboratories Inc. trades at a P/E ratio of 49.01, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 44.05 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 4.39 indicates a premium valuation even accounting for growth.
What is IDXX's risk profile compared to the market?
With a beta of 1.55, IDEXX Laboratories Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 15% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 29.50 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

22.80%

Operating Margin

31.70%

Return on Equity

59.30%

Return on Assets

23.00%

Revenue Growth (YoY)

3.60%

Earnings Growth (YoY)

5.30%

How profitable and efficient is IDXX's business model?
IDEXX Laboratories Inc. achieves a profit margin of 22.80%, meaning it retains $22.80 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 31.70% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 59.30% and ROA at 23.00%, the company generates strong returns on invested capital.
What are IDXX's recent growth trends?
IDEXX Laboratories Inc.'s revenue grew by 3.60% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 5.30% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry averages for proper context.

Company Size & Market

Shares Outstanding

80.42M

Book Value/Share

$17.93

Asset Type

Common Stock

What is IDXX's market capitalization and position?
IDEXX Laboratories Inc. has a market capitalization of $42.73B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 80.42M shares outstanding, the company's ownership is relatively concentrated. As a participant in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry, it competes with other firms in this sector.
How does IDXX's price compare to its book value?
IDEXX Laboratories Inc.'s book value per share is $17.93, while the current stock price is $565.19, resulting in a price-to-book (P/B) ratio of 31.52. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$507.08

10.28% downside potential

Analyst Recommendations

Strong Buy

3

Buy

3

Hold

6

Sell

0

Strong Sell

1

How reliable are analyst predictions for IDXX?
13 analysts cover IDXX with 46% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $507.08 implies -10.3% downside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on IDXX?
Current analyst recommendations:3 Strong Buy, 3 Buy, 6 Hold, 01 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 02:20 AM

Technical Indicators

What does IDXX's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret IDXX's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for IDXX and get notified when the price changes.

Stay Ahead of the Market with IDEXX Laboratories Inc. Alerts

Set up price alerts for IDEXX Laboratories Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.